Exploring the Potential Treatment for Mpox
Abstract
Monkeypox (Mpox) is a virus that originally infected only animals. Caused by the monkeypox virus, this infection presents with symptoms similar to smallpox. Although two years have passed since the 2022 outbreak, new cases continue to emerge monthly. Initially, human cases of mpox were confined to outbreaks in central and western Africa. However, the virus has recently spread globally, possibly due to a decline in vaccination rates. In this context, evidence for effective therapies, such as antivirals, is urgently needed. Three antivirals—tecovirimat, brincidofovir, and cidofovir—are known to have activity against the mpox virus. Their use is currently limited to expanded access for treating non-variola orthopoxvirus infections, with ongoing phase 3 trials. This review will discuss the mechanisms of action, clinical use, and efficacy of these antivirals.
Keywords
References
World Health Organization. Multi-country outbreak of mpox, External situation report#32 [Internet]. Weekly Epidemiological Record. 2024 [cited 2024 Nov 7]. Available from: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-32--30-april-2024
Huang Y, Mu L, Wang W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduct Target Ther. 2022;7(1):1–22.
World Health Organization. Clinical management and infection prevention and control for monkeypox: interim rapid response guidance, 10 June 2022. World Heal Organ [Internet]. 2022;(June). Available from: https://apps.who.int/iris/bitstream/handle/10665/355798/WHO-MPX-Clinical_and_IPC-2022.1-eng.pdf%0Ahttps://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1
Palanisamy PR, Elango D, Ananthy V, Subramanian U. Recent advances in the treatment of monkeypox drugs and vaccines. National Journal of Pharmacology and Therapeutics. 2023;1(2):65-9.
Gomez-Garberi M, Sarrio-Sanz P, Martinez-Cayuelas L, et al. Genitourinary lesions due to monkeypox. European Urology. 2022;82(6):625-30.
D'Antonio F, Pagani G, Buca D, Khalil A. Monkeypox infection in pregnancy: a systematic review and metaanalysis. American Journal of Obstetrics & Gynecology MFM. 2023;5(1):100747.
Islam MA, Ahammed T, Noor ST, Hasan MN, Hoque MN, Tiwari A, Harapan H, Dhama K, Islam T, Bhattacharya P. An estimation of five-decade long monkeypox case fatality rate: systematic review and meta-analysis. Journal of Pure and Applied Microbiology. 2022;16(suppl 1):3036-47.
Xia J, Huang CL, Chu P, Kroshinsky D. Eczema monkeypoxicum: report of monkeypox transmission in a patient with atopic dermatitis. JAAD Case Reports. 2022;29:95-9.9.
Sukhdeo S, Mishra S, Walmsley S. Human monkeypox: a comparison of the characteristics of the new epidemic to the endemic disease. BMC Infect Dis. 2022;22(1):1–13. Available from: https://doi.org/10.1186/s12879-022-07900-7
DeLaurentis CE, Kiser J, Zucker J. New perspectives on antimicrobial agents: tecovirimat for treatment of human monkeypox virus. Antimicrobial Agents and Chemotherapy. 2022;66(12):e01226-22.
Florescu DF, Keck MA. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Review of Anti-infective Therapy. 2014;12(10):1171-8.
Wang B, Cao B, Bei ZC, Xu L, Zhang D, Zhao L, Song Y, Wang H. Disulfide-incorporated lipid prodrugs of cidofovir: synthesis, antiviral activity, and release mechanism. European Journal of Medicinal Chemistry. 2023;258:115601.
Torres HM. Current options in the diagnosis and treatment of monkeypox. Current Fungal Infection Reports. 2022;16(4):234-9.
Russo AT, Grosenbach DW, Brasel TL, et al. Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques. The Journal of Infectious Diseases. 2018;218(9):1490-9.
Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. New England Journal of Medicine. 2018;379(1):44-53.
Aldred B, Lyles RH, Scott JY, et al. Early tecovirimat treatment for mpox disease among people with HIV. JAMA Internal Medicine. 2024;184(3):275-9.
Karmarkar EN, Golden MR, Kerani RP, et al. Association of tecovirimat therapy with mpox symptom improvement: a cross-sectional study—King County, Washington, May–October 2022. Open Forum Infectious Diseases. 2024;11(3)ofae029).
Mazzotta V, Cozzi‐Lepri A, Lanini S, et al. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox. Journal of Medical Virology. 2023;95(6):e28868.
Grossi IM, Foster SA, Gainey MR, Krile RT, Dunn JA, Brundage T, Khouri JM. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits. Antiviral Research. 2017;143:278-86.
Rao AK. Interim clinical treatment considerations for severe manifestations of mpox—United States, February 2023. MMWR. Morbidity and Mortality Weekly Report. 2023;72.
Foster SA, Parker S, Lanier R. The role of brincidofovir in preparation for a potential smallpox outbreak. Viruses. 2017;9(11):320.
Zalcman J, Pasternak Y, Kenan D, et al. Safety of Cidofovir treatment for suspected or confirmed adenovirus infection in immunocompetent pediatric population. The Pediatric Infectious Disease Journal. 2024;43(3):198-202.
Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral research. 2008;79(2):121-7.
Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrobial Agents and Chemotherapy. 2015;59(7):4296-300.
Olson VA, Smith SK, Foster S, Li Y, Lanier ER, Gates I, Trost LC, Damon IK. In vitro efficacy of brincidofovir against variola virus. Antimicrobial Agents and Chemotherapy. 2014;58(9):5570-1.
Stittelaar KJ, Neyts J, Naesens L, Van Amerongen G, Van Lavieren RF, Holý A, De Clercq E, Niesters HG, Fries E, Maas C, Mulder PG. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature. 2006;439(7077):745-8.
Hassan H, Abdelhamid HA, Mohamed M, Elsaid M. Monkeypox outbreak: an overview of potential therapeutic options. Current Treatment Options in Infectious Diseases. 2023;15(4):89-108.
Tempestilli M, Mondi A, D'Avolio A, Forini O, Pinnetti C, Mazzotta V, Gagliardini R, Beccacece A, De Nicolò A, Faccendini P, Cimini E. Pharmacokinetics of tecovirimat in subjects with Mpox. International Journal of Antimicrobial Agents. 2024;63(2):107068.
Shamim MA, Satapathy P, Padhi BK, et al. Pharmaceutical treatment of monkeypox virus: A narrative review and bibliometric analysis. 2022.
Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. Journal of Virology. 2005;79(20):13139-49.
Mertes H, Rezende AM, Brosius I, et al. Tecovirimat resistance in an immunocompromised patient with mpox and prolonged viral shedding. Annals of Internal Medicine. 2023;176(8):1141-3.
Kannan SR, Sachdev S, Reddy AS, Kandasamy SL, Byrareddy SN, Lorson CL, Singh K. Mutations in the monkeypox virus replication complex: potential contributing factors to the 2022 outbreak. Journal of Autoimmunity. 2022;133:102928.
Russo AT, Grosenbach DW, Chinsangaram J, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Review of Anti-infective Therapy. 2021;19(3):331-44.
Hermanussen L, Brehm TT, Wolf T, et al. Tecovirimat for the treatment of severe Mpox in Germany. Infection. 2023;51(5):1563-8.
Inada M, Saito S, Tsuzuki S, Okumura N, Sato L, Kamegai K, Sanada M, Komatsubara M, Shimojima M, Ebihara H, Kasuya F. Treatment with tecovirimat of the first two cases of monkeypox in Japan. Journal of Infection and Chemotherapy. 2023;29(4):418-21.
Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. The Lancet Infectious Diseases. 2022;22(8):1153-62.
Mailhe M, Beaumont AL, Thy M, et al. Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study. Clinical Microbiology and Infection. 2023;29(2):233-9.
Scandale P, Raccagni AR, Nozza S. Unilateral blepharoconjunctivitis due to monkeypox virus infection. Ophthalmology. 2022;129(11):1274.
Raccagni AR, Candela C, Bruzzesi E, Mileto D, Canetti D, Rizzo A, Castagna A, Nozza S. Real-life Use of Cidofovir for Treatment of Severe Monkeypox Cases. Journal of Medical Virology. 2022 Oct 13.
Desai AN, Thompson GR, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH. Compassionate use of tecovirimat for the treatment of monkeypox infection. JAMA. 2022;328(13):1348-50.
Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, Horby P, Olliaro P. Monkeypox treatment with tecovirimat in the Central African Republic under an Expanded Access Programme. MedRxiv. 2022:2022-08.
McLean J, Stoeckle K, Huang S, Berardi J, Gray B, Glesby MJ, Zucker J. Tecovirimat treatment of people with HIV during the 2022 mpox outbreak: a retrospective cohort study. Annals of internal medicine. 2023;176(5):642-8.
Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2020;38(3):644-54.
Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, Foster SA. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2019;25(2):369-81.
Mazurkov OY, Kabanov AS, Shishkina LN, Sergeev AA, Skarnovich MO, Bormotov NI, Skarnovich MA, Ovchinnikova AS, Titova KA, Galahova DO, Bulychev LE. New effective chemically synthesized anti-smallpox compound NIOCH-14. Journal of General Virology. 2016;97(5):1229-39.
Smee DF, Bailey KW, Sidwell RW. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antiviral Chemistry and Chemotherapy. 2000;11(4):303-9.
Raghuvanshi R, Bharate SB. Recent developments in the use of kinase inhibitors for management of viral infections. Journal of Medicinal Chemistry. 2021;65(2):893-921.
Khani E, Afsharirad B, Entezari‐Maleki T. Monkeypox treatment: current evidence and future perspectives. Journal of Medical Virology. 2023;95(1):e28229.
Refbacks
- There are currently no refbacks.
This work is licensed under a